Jeffrey L Platt

List of Publications by Year in descending order

158 papers	8,971 citations	41344 49 h-index	42399 92 g-index
165 all docs	165 docs citations	165 times ranked	5801 citing authors

#	Article	IF	Citations
1	Receptor-Mediated Monitoring of Tissue Well-Being Via Detection of Soluble Heparan Sulfate by Toll-Like Receptor 4. Journal of Immunology, 2002, 168, 5233-5239.	0.8	605
2	Transplantation of discordant xenografts: a review of progress. Trends in Immunology, 1990, 11, 450-456.	7.5	533
3	Human complement regulatory proteins protect swine-to-primate cardiac xenografts from humoral injury. Nature Medicine, 1995, 1, 423-427.	30.7	531
4	IMMUNOPATHOLOGY OF HYPERACUTE XENOGRAFT REJECTION IN A SWINE-TO-PRIMATE MODEL. Transplantation, 1991, 52, 214-220.	1.0	418
5	Biological implications of cell fusion. Nature Reviews Molecular Cell Biology, 2005, 6, 567-575.	37.0	284
6	Transplantation of discordant xenografts: a challenge revisited. Trends in Immunology, 1996, 17, 373-378.	7.5	227
7	Heme oxygenase: Protective gene or Trojan horse. Nature Medicine, 1998, 4, 1364-1365.	30.7	221
8	Cutting Edge: An Endogenous Pathway to Systemic Inflammatory Response Syndrome (SIRS)-Like Reactions through Toll-Like Receptor 4. Journal of Immunology, 2004, 172, 20-24.	0.8	220
9	Role of heparan sulfate in immune system-blood vessel interactions. Trends in Immunology, 1993, 14, 500-505.	7.5	198
10	Donor-specific B-cell tolerance after ABO-incompatible infant heart transplantation. Nature Medicine, 2004, 10, 1227-1233.	30.7	197
11	ABO-incompatible kidney transplantation using both A2 and non-A2 living donors. Transplantation, 2003, 75, 971-977.	1.0	187
12	Accommodation in ABO-Incompatible Kidney Allografts, a Novel Mechanism of Self-Protection Against Antibody-Mediated Injury. American Journal of Transplantation, 2003, 3, 952-960.	4.7	177
13	MOLECULAR BARRIERS TO XENOTRANSPLANTATION1. Transplantation, 1996, 62, 303-310.	1.0	175
14	THE ROLE OF ANTI-GAL??1-3GAL ANTIBODIES IN ACUTE VASCULAR REJECTION AND ACCOMMODATION OF XENOGRAFTS1. Transplantation, 2000, 70, 1667-1674.	1.0	132
15	Accommodation: Preventing Injury in Transplantation and Disease. Journal of Immunology, 2004, 172, 5143-5148.	0.8	129
16	Treatment of cirrhosis and liver failure in rats by hepatocyte xenotransplantation. Gastroenterology, 2003, 124, 422-431.	1.3	127
17	AN ELSIA ASSAY FOR XENOREACTIVE NATURAL ANTIBOIDES. Transplantation, 1990, 49, 1000-1001.	1.0	124
18	Shedding of heparan sulfate proteoglycan by stimulated endothelial cells: Evidence for proteolysis of cell-surface molecules. Journal of Cellular Physiology, 1996, 168, 625-637.	4.1	111

#	Article	IF	Citations
19	Regional manifestations and control of the immune system. FASEB Journal, 2002, 16, 849-856.	0.5	111
20	Phenotypic and Functional Maturation of Dendritic Cells Mediated by Heparan Sulfate. Journal of Immunology, 2000, 165, 1599-1604.	0.8	106
21	Host conditioning and rejection monitoring in hepatocyte transplantation in humans. Journal of Hepatology, 2017, 66, 987-1000.	3.7	99
22	Evolutionary clues to the functions of the Toll-like family as surveillance receptors. Trends in Immunology, 2003, 24, 19-24.	6.8	96
23	A Perspective on Xenograft Rejection and Accommodation1. Immunological Reviews, 1994, 141, 127-149.	6.0	94
24	Humoral Responses to Pig-to-Baboon Cardiac Transplantation: Implications for the Pathogenesis and Treatment of Acute Vascular Rejection and for Accommodation. Human Immunology, 1997, 58, 91-105.	2.4	93
25	Immunosuppression by Embryonic Stem Cells. Stem Cells, 2008, 26, 89-98.	3.2	93
26	Physiologic and Immunologic Hurdles to Xenotransplantation. Journal of the American Society of Nephrology: JASN, 2001, 12, 182-193.	6.1	89
27	Endothelial Cell Activation by Pore-Forming Structures. Circulation, 2000, 101, 1867-1873.	1.6	87
28	Prolonged Survival of Porcine Hepatocytes in Cynomolgus Monkeys. Gastroenterology, 2007, 132, 321-329.	1.3	86
29	C4d and the Fate of Organ Allografts. Journal of the American Society of Nephrology: JASN, 2002, 13, 2417-2419.	6.1	84
30	ABSENCE OF HYPERACUTE REJECTION IN NEWBORN PIG-TO-BABOON CARDIAC XENOGRAFTS. Transplantation, 1995, 59, 1-6.	1.0	81
31	Acute Vascular Rejection and Accommodation: Divergent Outcomes of the Humoral Response to Organ Transplantation. Transplantation, 2004, 78, 1471-1478.	1.0	81
32	Xenotransplantation and other means of organ replacement. Nature Reviews Immunology, 2001, 1, 154-160.	22.7	79
33	B Cell-Dependent TCR Diversification. Journal of Immunology, 2004, 172, 4709-4716.	0.8	75
34	Modulation of macrophage and B cell function by glycosaminoglycans. Journal of Leukocyte Biology, 1999, 66, 391-400.	3.3	74
35	Regulation of platelet heparanase during inflammation: Role of pH and proteinases. Journal of Cellular Physiology, 1998, 175, 255-267.	4.1	71
36	Spontaneous fusion of cells between species yields transdifferentiation and retroviral transfer in vivo. FASEB Journal, 2004, 18, 548-550.	0.5	70

#	Article	IF	Citations
37	Proteoglycan metabolism associated with mouse metanephric development: Morphologic and biochemical effects of Î²-d-xyloside. Developmental Biology, 1987, 123, 293-306.	2.0	67
38	Isohemagglutinins and xenoreactive antibodies. Human Immunology, 1996, 45, 94-104.	2.4	65
39	A genetic basis for the â€œAdonisâ€•phenotype of low adiposity and strong bones. FASEB Journal, 2004, 18, 1282-1284.	0.5	64
40	Accommodation in organ transplantation. Current Opinion in Organ Transplantation, 2008, 13, 165-170.	1.6	61
41	Chronic rejection of mouse kidney allografts. Kidney International, 1999, 55, 1935-1944.	5.2	57
42	Sirolimus affects cardiomyocytes to reduce left ventricular mass in heart transplant recipients. European Heart Journal, 2008, 29, 2742-2750.	2.2	54
43	Accommodation in renal transplantation: unanswered questions. Current Opinion in Organ Transplantation, 2010, 15, 481-485.	1.6	54
44	Cell Fusion Connects Oncogenesis with Tumor Evolution. American Journal of Pathology, 2015, 185, 2049-2060.	3.8	53
45	Natural mechanisms for evading graft rejection: the fetus as an allograft. Seminars in Immunopathology, 2003, 25, 95-117.	4.0	52
46	Specificity and function of "natural" antibodies in immunodeficient subjects: clues to B cell lineage and development. Journal of Clinical Immunology, 1997, 17, 311-321.	3.8	51
47	New risks, new gains. Nature, 2000, 407, 27-29.	27.8	51
48	Accommodation of grafts: Implications for health and disease. Human Immunology, 2007, 68, 645-651.	2.4	51
49	MECHANISMS OF INJURY IN PORCINE LIVERS PERFUSED WITH BLOOD OF PATIENTS WITH FULMINANT HEPATIC FAILURE. Transplantation, 1994, 58, 1162-1170.	1.0	51
50	Effacing of the T Cell Compartment by Cardiac Transplantation in Infancy. Journal of Immunology, 2006, 176, 1962-1967.	0.8	50
51	Molecular and Cellular Mechanisms of Mammalian Cell Fusion. Advances in Experimental Medicine and Biology, 2011, 713, 33-64.	1.6	48
52	Apoptosis and Cellular Activation in the Pathogenesis of Acute Vascular Rejection. Circulation Research, 2002, 91, 1135-1141.	4.5	44
53	Heparin and heparan sulfate delimit nephron formation in fetal metanephric kidneys. Developmental Biology, 1990, 139, 338-348.	2.0	43
54	Pathways to Acute Humoral Rejection. American Journal of Pathology, 2004, 164, 1073-1080.	3.8	43

#	Article	IF	Citations
55	Intrinsic Resistance of Hepatocytes to Complement-Mediated Injury. Journal of Immunology, 2005, 174, 7302-7309.	0.8	41
56	PLATELET-MEDIATED ACTIVATION OF ENDOTHELIAL CELLS: IMPLICATIONS FOR THE PATHOGENESIS OF TRANSPLANT REJECTION1. Transplantation, 2001, 72, 509-515.	1.0	40
57	TACI deficiency enhances antibody avidity and clearance of an intestinal pathogen. Journal of Clinical Investigation, 2014, 124, 4857-4866.	8.2	40
58	Differential Regulation of Endothelial Cell Activation by Complement and Interleukin 1Î±. Circulation Research, 2006, 98, 793-800.	4.5	39
59	Immunochemical properties of anti-Gal alpha 1-3Gal antibodies after sensitization with xenogeneic tissues. Journal of Clinical Immunology, 1999, 19, 116-126.	3.8	38
60	The etiology of sepsis: turned inside out. Trends in Molecular Medicine, 2006, 12, 10-16.	6.7	38
61	Propagation and Control of T Cell Responses by Heparan Sulfate-Bound IL-2. Journal of Immunology, 2003, 170, 5470-5474.	0.8	36
62	Chondroitin sulfate proteoglycan synthesis and reutilization of Î²-d-xyloside-initiated chondroitin/dermatan sulfate glycosaminoglycans in fetal kidney branching morphogenesis. Developmental Biology, 1989, 133, 515-528.	2.0	35
63	Accommodation in <scp>ABO</scp>â€incompatible organ transplants. Xenotransplantation, 2018, 25, e12418.	2.8	35
64	The role of complement in transplantation. Molecular Immunology, 1999, 36, 965-971.	2.2	32
65	Influence of human fulminant hepatic failure sera on endogenous retroviral expression in pig hepatocytes. Liver Transplantation, 2000, 6, 76-84.	2.4	32
66	Xenotransplantation and the Future of Renal Replacement. Journal of the American Society of Nephrology: JASN, 2004, 15, 1106-1112.	6.1	32
67	The Paradoxical Functions of B Cells and Antibodies in Transplantation. Journal of Immunology, 2013, 190, 875-879.	0.8	31
68	The role of antibodies in transplantation. Transplantation Reviews, 2009, 23, 191-198.	2.9	30
69	B cells in transplantation. Journal of Heart and Lung Transplantation, 2016, 35, 704-710.	0.6	29
70	The Future Promises of Xenotransplantation a,b. Annals of the New York Academy of Sciences, 1998, 862, 5-18.	3.8	28
71	Fusion of approaches to the treatment of organ failure. American Journal of Transplantation, 2004, 4, 74-77.	4.7	28
72	Cell Fusion in the War on Cancer: A Perspective on the Inception of Malignancy. International Journal of Molecular Sciences, 2016, 17, 1118.	4.1	28

#	Article	IF	Citations
73	ANTIGEN EXPRESSION IN XENOTRANSPLANTATION: HOW LOW MUST IT GO?. Transplantation, 2001, 71, 313-319.	1.0	25
74	Xenotransplantation: Progress Along Paths Uncertain from Models to Application. ILAR Journal, 2018, 59, 286-308.	1.8	24
75	Fitness of Cell-Mediated Immunity Independent of Repertoire Diversity. Journal of Immunology, 2007, 178, 2950-2960.	0.8	23
76	C3d regulates immune checkpoint blockade and enhances antitumor immunity. JCI Insight, 2017, 2, .	5.0	23
77	Antibodies in transplantation. Discovery Medicine, 2010, 10, 125-33.	0.5	23
78	IgM in the kidney: a multiple personality disorder. Kidney International, 2015, 88, 439-441.	5.2	22
79	MODULATION OF CYTOLYTIC T CELL RESPONSES BY HEPARAN SULFATE. Transplantation, 1994, 57, 1087-1094.	1.0	21
80	Direct measurement of lymphocyte receptor diversity. Nucleic Acids Research, 2003, 31, 139e-139.	14.5	21
81	Escaping From Rejection. Transplantation, 2009, 88, 1233-1236.	1.0	21
82	Donor specific antibodies after transplantation. Pediatric Transplantation, 2011, 15, 686-690.	1.0	21
83	Toward Development and Production of Human T Cells in Swine for Potential Use in Adoptive T Cell Immunotherapy. Tissue Engineering - Part A, 2009, 15, 1031-1040.	3.1	20
84	Lessons from cardiac transplantation in infancy. Pediatric Transplantation, 2009, 13, 814-819.	1.0	19
85	New and old technologies for organ replacement. Current Opinion in Organ Transplantation, 2013, 18, 179-185.	1.6	19
86	Accommodation and related conditions in vascularized composite allografts. Current Opinion in Organ Transplantation, 2017, 22, 470-476.	1.6	19
87	ROLE OF COMPLEMENT IN XENOTRANSPLANTATION. Clinical and Experimental Pharmacology and Physiology, 1999, 26, 1016-1019.	1.9	18
88	Knocking out xenograft rejection. Nature Biotechnology, 2002, 20, 231-232.	17.5	18
89	Induction of Human Blood Group A Antigen Expression on Mouse Cells, Using Lentiviral Gene Transduction. Human Gene Therapy, 2010, 21, 877-890.	2.7	18
90	Heparan Sulfate in Immune Responses. Annals of the New York Academy of Sciences, 1996, 797, 127-139.	3.8	17

#	Article	IF	Citations
91	Prospects for xenotransplantation. Pediatric Transplantation, 1999, 3, 193-200.	1.0	17
92	Basic mechanisms of humoral rejection. Pediatric Transplantation, 2005, 9, 9-16.	1.0	17
93	Endothelial Cell Responses to Complement Activation. , 1998, , 335-353.		17
94	New Technologies for Organ Replacement and Augmentation. Mayo Clinic Proceedings, 2005, 80, 370-378.	3.0	16
95	The role of B cell immunity in VCA graft rejection and acceptance. Human Immunology, 2019, 80, 385-392.	2.4	16
96	A Symposium on Donorâ€Specific Antibodies after Transplantation Introduction. Pediatric Transplantation, 2011, 15, 455-457.	1.0	15
97	Cell Fusion in Malignancy: A Cause or Consequence? A Provocateur or Cure?. Cells, 2019, 8, 587.	4.1	15
98	Coming to Terms with Reality: Why Xenotransplantation Is a Necessity. , 0, , 29-51.		15
99	Heparan Sulfate Proteoglycan Metabolism and the Fate of Grafted Tissues. Advances in Experimental Medicine and Biology, 2015, 865, 123-140.	1.6	14
100	The five dimensions of B cell tolerance. Immunological Reviews, 2019, 292, 180-193.	6.0	13
101	Xenotransplantationâ€”caution, but no moratorium. Nature Medicine, 1998, 4, 372-372.	30.7	12
102	The Immunological Hurdles to Cardiac Xenotransplantation. Journal of Cardiac Surgery, 2001, 16, 439-447.	0.7	12
103	And Justice for All. Circulation, 2010, 121, 1884-1886.	1.6	12
104	A MOLECULAR EPIDEMIOLOGICAL PROBE FOR PIG MICROCHIMERISM1. Transplantation, 1997, 64, 347-350.	1.0	12
105	The footprint of antibody bound to pig cells: evidence of complex surface topology. Biochemical and Biophysical Research Communications, 2003, 301, 751-757.	2.1	11
106	Constitutive Repression of Interleukin-1Î± in Endothelial Cells. Circulation Research, 2008, 102, 823-830.	4.5	11
107	Accommodation: How You See It, How You Donâ€™t. American Journal of Transplantation, 2011, 11, 2007-2008.	4.7	11
108	The Future of Transplantation. New England Journal of Medicine, 2022, 387, 77-78.	27.0	10

#	Article	IF	Citations
109	Quantitative evaluation of porcine endothelial cell antigens recognized by human natural antibodies: An analysis by Western blotting. Xenotransplantation, 1996, 3, 120-127.	2.8	9
110	Sensitization with Xenogeneic Tissues Alters the Heavy Chain Repertoire of Human Anti-GalÎ±1â€“3Gal Antibodies. Transplantation, 2005, 80, 102-109.	1.0	9
111	Toward a solution for cardiac failure in the newborn. Xenotransplantation, 2018, 25, e12479.	2.8	9
112	C1 Inhibitor for Prophylaxis of Xenograft Rejection After Pig to Cynomolgus Monkey Kidney Transplantation. Transplantation 2002: 73: 688.. Transplantation, 2002, 73, 675-677.	1.0	9
113	Non-canonical B cell functions in transplantation. Human Immunology, 2019, 80, 363-377.	2.4	8
114	Clinical xenotransplantation of the heart: At the watershed. Journal of Heart and Lung Transplantation, 2020, 39, 758-760.	0.6	8
115	Noncognate function of B cells in transplantation. Transplant International, 2009, 22, 593-598.	1.6	7
116	Novel functions of B cells in transplantation. Current Opinion in Organ Transplantation, 2011, 16, 61-68.	1.6	7
117	Harnessing B cells in immunotherapy. Immunotherapy, 2016, 8, 237-239.	2.0	7
118	TNFRSF13B Diversification Fueled by B Cell Responses to Environmental Challengesâ€”A Hypothesis. Frontiers in Immunology, 2021, 12, 634544.	4.8	7
119	The humoral barrier to transplantation of the liver: Is it more real than apparent?. Liver Transplantation, 2001, 7, 90-92.	2.4	6
120	Cellular antigens in nephroblastoma: Identification with monoclonal antibodies which recognize hemopoietic cells. Clinical Immunology and Immunopathology, 1987, 43, 110-116.	2.0	5
121	Xenotransplantation: The Need, The Immunologic Hurdles, and The Prospects For Success. ILAR Journal, 1995, 37, 22-31.	1.8	5
122	Approaches to the replacement of the function of failing organs. Current Opinion in Organ Transplantation, 2002, 7, 28-34.	1.6	5
123	Humoral immunity in xenotransplantation. Current Opinion in Organ Transplantation, 2004, 9, 170-175.	1.6	5
124	Limited Expansion of Human Hepatocytes in FAH/RAG2-Deficient Swine. Tissue Engineering - Part A, 2022, 28, 150-160.	3.1	5
125	Toward a modern concept of sepsis: new answers to ancient questions. Discovery Medicine, 2006, 6, 11-7.	0.5	5
126	TNFRSF13B genotypes control immune-mediated pathology by regulating the functions of innate B cells. JCI Insight, 2021, 6, .	5.0	4

#	Article	IF	Citations
127	Genetic therapies and xenotransplantation. Expert Opinion on Investigational Drugs, 1999, 8, 1653-1662.	4.1	3
128	B Cells in Transplantation of Rat, Mouse, and Man. Transplantation, 2018, 102, 357-358.	1.0	3
129	A Primer on Xenotransplantation. , 0, , 1-28.		3
130	Prevention of Infection in Xenotransplantation. , 0, , 261-290.		3
131	The mutable vaccine for mutable viruses. Immunotherapy, 2017, 9, 659-667.	2.0	2
132	Zoonotic Agents in Swine-to-Human Xenotransplants. , 0, , 217-238.		2
133	Insights from the immunopathology of transplantation. Seminars in Immunopathology, 2003, 25, 91-94.	4.0	1
134	Xenotransplantation of the liver: Is more complement control needed?. Liver Transplantation, 2001, 7, 933-934.	2.4	1
135	The Immunologic Barriers to Replacing Damaged Organs. Current Immunology Reviews, 2006, 2, 65-72.	1.2	1
136	Durable targeting of B-lymphocytes in living mice. Scientific Reports, 2018, 8, 11143.	3.3	1
137	Regulation of platelet heparanase during inflammation: Role of pH and proteinases. , 1998, 175, 255.		1
138	Xenotransplantation as a Vector for Infection. , 0, , 191-206.		1
139	The Complement System as a Hurdle to Xenotransplantation. , 0, , 53-83.		1
140	Regional delivery of immunosuppression for transplantation of vascularized composite allografts: opportunities near and far. Annals of Translational Medicine, 2021, 9, 0-0.	1.7	1
141	Xenotransplanation in Pharmaceutical Biotechnology. , 2005, , 265-279.		0
142	Interaction of Embryonic Stem Cells with the Immune System. , 2013, , 49-67.		0
143	Extracellular DNA in plasma: From marking to dissecting the cell biology of cardiac transplants. Journal of Heart and Lung Transplantation, 2018, 37, 945-947.	0.6	0
144	38227 Specific and highly potent human monoclonal antibodies against SARS-CoV-2. Journal of Clinical and Translational Science, 2021, 5, 21-21.	0.6	0

#	Article	IF	Citations
145	The Immunologic Barriers of Xenotransplantation and Application of Genetic Engineering. , 2002, , 323-347.		0
146	B cell selection is a function of the postâ€natal thymus. FASEB Journal, 2008, 22, 847.1.	0.5	0
147	Cell fusion causes DNA doubleâ€stranded breaks and transformation. FASEB Journal, 2011, 25, .	0.5	0
148	Accommodation and the Fetus. , 2013, , 79-85.		0
149	Recognition of Foreign Antigen and Foreign Major Histocompatibility Complex. , 0, , 175-189.		0
150	NK Cells as a Barrier to Xenotransplantation. , 0, , 85-98.		0
151	Therapeutic Strategies for Xenotransplantation. , 0, , 117-135.		0
152	Cellular Immune Responses to Xenografts. , 0, , 99-115.		0
153	Retroviruses and Xenotransplantation. , 0, , 239-250.		0
154	Potential Medical Impact of Endogenous Retroviruses. , 0, , 251-259.		0
155	Complement Regulation and the Host Response to Infection. , 0, , 159-174.		0
156	Cardiac Xenotransplantation. , 2017, , 549-562.		0
157	On Poetry and Vascularized Composite Allografting. Transplantation, 2020, 104, 1995-1996.	1.0	0
158	Lessons from ABO-Incompatible Cardiac Allotransplantation in the Newborn. , 2020, , 191-201.		0